Martin Hellmich

Mar 13, 2024 | nature.com | Julie George |Lukas Maas |Nima Abedpour |Laura S. Kaiser |Andreas Scheel |Martin Hellmich | +11 more

AbstractThe evolutionary processes that underlie the marked sensitivity of small cell lung cancer (SCLC) to chemotherapy and rapid relapse are unknown1,2,3. Here we determined tumour phylogenies at diagnosis and throughout chemotherapy and immunotherapy by multiregion sequencing of 160 tumours from 65 patients.